Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

April 24, 2026 updated by: Immunovant Sciences GmbH

An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)

This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
109

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Australia
      • Sydney, Australia, 2000
        • Site Number - 7565
  • Belgium
      • Bruges, Belgium, 8000
        • Site Number - 4671
      • Brussels, Belgium, 1070
        • Site Number - 4672
      • Brussels, Belgium, 1200
        • Site Number - 4673
      • Ghent, Belgium, B-9000
        • Site Number - 4670
  • Georgia
      • Tbilisi, Georgia, 114
        • Site Number - 3454
      • Tbilisi, Georgia, 114
        • Site Number - 3455
      • Tbilisi, Georgia, 159
        • Site Number - 3450
      • Tbilisi, Georgia, 159
        • Site Number - 3451
  • Hungary
      • Budapest, Hungary, 1133
        • Site Number - 7550
      • Pécs, Hungary, 7623
        • Site Number - 7552
  • Israel
      • Afula, Israel, 1834111
        • Site Number - 4764
      • Jerusalem, Israel, 91120
        • Site Number - 4761
      • Petah Tikva, Israel, 4941492
        • Site Number - 4762
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israel, 5265601
        • Site Number - 4760
  • Italy
      • Catania, Italy, CAP95125
        • Site Number - 6207
      • Milan, Italy, 20122
        • Site Number - 6204
      • Milan, Italy, 20149
        • Site Number - 6203
      • Naples, Italy, 80131
        • Site Number - 6205
      • Palermo, Italy, 90127
        • Site Number - 6209
      • Pisa, Italy, 56124
        • Site Number - 6201
      • Rome, Italy, 00189
        • Site Number - 6202
  • Latvia
      • Ogre, Latvia, LV-5001
        • Site Number - 9301
      • Riga, Latvia, LV-1006
        • Site Number - 9300
      • Ventspils, Latvia, LV3601
        • Site Number - 9302
  • New Zealand
      • Christchurch, New Zealand, 8013
        • Site Number - 7570
  • Poland
      • Krakow, Poland, 30-688
        • Site Number - 3101
      • Lublin, Poland, 20-171
        • Site Number - 3104
      • Lublin, Poland, 60-354
        • Site Number - 3105
    • Silesian Voivodeship
      • Gliwice, Silesian Voivodeship, Poland, 44-102
        • Site Number - 3107
  • Puerto Rico
      • San Juan, Puerto Rico, 00921
        • Site Number - 1990
  • Slovakia
      • Bratislava, Slovakia, 82606
        • Site Number - 9200
      • Bratislava, Slovakia
        • Site Number - 9201
      • Trenčín, Slovakia, 91101
        • Site Number - 9202
  • Spain
      • Madrid, Spain, 28034
        • Site Number - 3604
      • Santiago de Compostela, Spain, 15706
        • Site Number - 3600
      • Seville, Spain, 41009
        • Site Number - 3606
      • Valencia, Spain, 46026
        • Site Number - 3603
    • Catalonia
      • Barcelona, Catalonia, Spain, 8006
        • Site Number - 3602
  • United Kingdom
      • Guildford, United Kingdom, GU2 7XX
        • Site Number - 7305
      • London, United Kingdom, EC1V 2PD
        • Site Number - 7303
      • London, United Kingdom, W1T 6AH
        • Site Number - 7312
      • London, United Kingdom, W1T 7HA
        • Site Number - 7313
      • Manchester, United Kingdom, M139WL
        • Site Number - 7300
      • Newcastle upon Tyne, United Kingdom, NE1 3BZ
        • Site Number - 7302
      • Sheffield, United Kingdom, S102SB
        • Site Number - 7308
  • United States
    • California
      • Glendora, California, United States, 91741
        • Site Number - 1520
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Site Number - 1501
    • Michigan
      • Livonia, Michigan, United States, 48152
        • Site Number - 1526
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Site Number - 1513
    • Nevada
      • Las Vegas, Nevada, United States, 89184
        • Site Number - 1540
    • Texas
      • Houston, Texas, United States, 77030
        • Site Number - 1508
      • Mesquite, Texas, United States, 75149
        • Site Number - 1558
    • West Virginia
      • Morgantown, West Virginia, United States, 26506
        • Site Number - 1511
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Site Number - 1518

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

For all participants:

1. Have completed the Week 24 visit of the feeder study.

For participants assigned to the Open-label Treatment Cohort:

  1. Do not require immediate surgical intervention and is not planning corrective surgery/irradiation or medical therapy for TED during the course of the study.
  2. Did not permanently discontinue batoclimab

Additional inclusion criteria are defined in the protocol.

Exclusion criteria:

For all participants:

1. In the Investigator's judgement, the benefits of entry in the study do not outweigh the risk.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Other: Observational cohort
Proptosis responders in feeder studies will enter in a non-treatment observational study
Other: Observational cohort study
Observational cohort study
Experimental: Treatment Cohort
Proptosis non-responders in feeder studies will be administered batoclimab of 680 milligram (mg) subcutaneous (SC) for 12 weeks followed by 340 mg SC for 12 weeks
Drug: Batoclimab
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Other Names:
  • IMVT-1401

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Duration of proptosis response off treatment in study eye in batoclimab responder participants in the feeder studies
Time Frame: Up to Week 24
Up to Week 24

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Percentage of proptosis responders in study eye in placebo non-responder participants in the feeder studies
Time Frame: At Week 24
At Week 24
Percentage of proptosis responders in study eye in batoclimab non-responder participants in the feeder studies
Time Frame: At Week 24
At Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Immunovant Sciences GmbH

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 6, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 2, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 2, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 24, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 24, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 26, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 29, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 24, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IMVT-1401-3203

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings